BioRestorative Therapies (BRTX) Consolidated Net Income (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Consolidated Net Income came in at -$26.4 million in Q4 2025, down 866.17% YoY from $3.4 million in Q4 2024, and down 612.03% on a QoQ basis from -$3.7 million in Q3 2025.
BioRestorative Therapies (BRTX) Consolidated Net Income (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Consolidated Net Income data on file, last reported at -$26.4 million in Q4 2025.
- Quarterly Consolidated Net Income fell 866.17% year-over-year to -$26.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$39.2 million (down 233.85% YoY) and the FY2025 annual result came in at -$38.2 million, up 6.73% from the prior year.
- Consolidated Net Income eased to -$26.4 million in Q4 2025, from -$3.7 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$2.3 million in Q3 2024 to a low of -$26.4 million in Q4 2025.
- A 5-year average of -$5.6 million and a median of -$4.2 million in 2021 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2021 — Consolidated Net Income tumbled 1178.06% — and 2022, when it soared 66.25%.
- Tracing BRTX's Consolidated Net Income over 5 years: stood at -$4.0 million in 2021, then decreased by 16.64% to -$4.7 million in 2022, then surged by 30.91% to -$3.3 million in 2023, then advanced by 16.22% to -$2.7 million in 2024, then plunged by 866.17% to -$26.4 million in 2025.
- The last three Consolidated Net Income figures came in at -$26.4 million (Q4 2025), -$3.7 million (Q3 2025), and -$3.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | -3.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -26.41 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Jun 30, 2025 | -3.68 Mn |
| Mar 31, 2025 | -5.37 Mn |
| Dec 31, 2024 | -2.73 Mn |
| Sep 30, 2024 | -2.29 Mn |
| Jun 30, 2024 | -2.47 Mn |
| Mar 31, 2024 | -4.24 Mn |
| Dec 31, 2023 | -3.26 Mn |
| Sep 30, 2023 | -3.12 Mn |
| Jun 30, 2023 | -3.14 Mn |
| Mar 31, 2023 | -5.82 Mn |
| Dec 31, 2022 | -4.72 Mn |
| Sep 30, 2022 | -4.66 Mn |
| Jun 30, 2022 | -4.69 Mn |
| Mar 31, 2022 | -5.09 Mn |
| Dec 31, 2021 | -4.05 Mn |
| Sep 30, 2021 | -4.18 Mn |
| Jun 30, 2021 | -4.14 Mn |
| Mar 31, 2021 | -15.09 Mn |